AEON · AEON Biopharma, Inc.
The AI's read
This gives AEON a clearer plan for testing whether its medicine matches BOTOX. The company has submitted its study application and plans to begin the study in the first quarter of 2027. The FDA has not approved the medicine. Earlier study results can support AEON's case only after scientific links are shown, and the FDA asked for more analysis on migraine. The added cash and clearer study path are encouraging, but approval is still ahead.